Allergen Research Corporation Renamed Aimmune Therapeutics
May 27 2015 - 6:00PM
Business Wire
Aimmune Therapeutics, Inc., a privately held biopharmaceutical
company developing desensitization treatments for food allergies,
today announced that the company has changed its name from Allergen
Research Corporation (ARC) to Aimmune Therapeutics.
As Aimmune Therapeutics, the company has introduced a new
corporate identity and logo that honors its heritage while
reflecting its evolution and steadfast mission: to address the
urgent and growing unmet need to protect people with food allergies
from the dangers of accidental exposure to their allergens. For
more information, please see Aimmune’s new website at
www.aimmune.com.
About Food Allergies
Food allergies are a significant and growing health problem in
the United States, Europe and throughout the developed world. It is
estimated that more than 30 million people in the United States and
Europe have a food allergy. The prevalence of food peanut allergy
in children in the United States is estimated to have increased at
a constant annual growth rate of 10 percent between 1997 and 2008,
and experts believe it has continued to rise. For people living
with food allergies, certain foods can cause severe allergic
reactions, including potentially life-threatening anaphylaxis.
There is no cure for food allergies. Currently, food-allergic
patients manage their condition by strict allergen avoidance and
carrying epinephrine auto-injectors for use in case of accidental
exposure. Thus, in addition to the unmet medical need, food
allergies can impose a significant quality of life burden. For more
information, please see www.foodallergy.org and
www.niaid.nih.gov/topics/foodallergy.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research
Corporation (ARC), is a clinical-stage biopharmaceutical company
developing treatments for peanut and other food allergies. Aimmune
Therapeutics’ characterized oral desensitization immunotherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), combines
proprietary product candidates with gradual, controlled up-dosing
protocols to obtain meaningful desensitization to food allergens.
Aimmune Therapeutics recently completed a Phase 2 study of its lead
product, AR101, a standardized, complex mixture of 13 naturally
occurring proteins and pharmaceutical-grade ingredients for the
treatment of peanut allergy, one of the most common food allergies.
Aimmune Therapeutics is also developing products for other common
food allergies for use with the CODIT system. For more information,
please see www.aimmune.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150527006660/en/
EdelmanAmanda Breeding,
415-229-7649amanda.breeding@edelman.com